Crispr Theraptc (CRSP) Director Kurt Von Emster Sells 35,473 Shares

Crispr Theraptc (NASDAQ:CRSP) Director Kurt Von Emster sold 35,473 shares of the company’s stock in a transaction that occurred on Tuesday, August 8th. The stock was sold at an average price of $18.63, for a total value of $660,861.99. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Kurt Von Emster also recently made the following trade(s):

  • On Thursday, August 17th, Kurt Von Emster sold 34,141 shares of Crispr Theraptc stock. The stock was sold at an average price of $19.06, for a total value of $650,727.46.
  • On Tuesday, August 15th, Kurt Von Emster sold 55,569 shares of Crispr Theraptc stock. The shares were sold at an average price of $19.59, for a total value of $1,088,596.71.
  • On Friday, August 4th, Kurt Von Emster sold 50,477 shares of Crispr Theraptc stock. The shares were sold at an average price of $17.81, for a total value of $898,995.37.
  • On Tuesday, August 1st, Kurt Von Emster sold 5,512 shares of Crispr Theraptc stock. The shares were sold at an average price of $17.51, for a total value of $96,515.12.
  • On Friday, July 28th, Kurt Von Emster sold 41,312 shares of Crispr Theraptc stock. The shares were sold at an average price of $17.63, for a total value of $728,330.56.
  • On Wednesday, July 26th, Kurt Von Emster sold 32,930 shares of Crispr Theraptc stock. The shares were sold at an average price of $17.60, for a total value of $579,568.00.
  • On Friday, July 14th, Kurt Von Emster sold 69,859 shares of Crispr Theraptc stock. The shares were sold at an average price of $16.84, for a total value of $1,176,425.56.
  • On Wednesday, July 12th, Kurt Von Emster sold 31,992 shares of Crispr Theraptc stock. The shares were sold at an average price of $16.56, for a total value of $529,787.52.
  • On Wednesday, July 5th, Kurt Von Emster sold 4,254 shares of Crispr Theraptc stock. The shares were sold at an average price of $16.26, for a total value of $69,170.04.
  • On Thursday, June 29th, Kurt Von Emster sold 43,202 shares of Crispr Theraptc stock. The shares were sold at an average price of $16.90, for a total value of $730,113.80.

Shares of Crispr Theraptc (NASDAQ CRSP) traded down 0.43% during mid-day trading on Friday, reaching $18.34. The company’s stock had a trading volume of 60,044 shares. The firm’s market capitalization is $744.44 million. The company’s 50-day moving average is $17.38 and its 200 day moving average is $17.51. Crispr Theraptc has a 1-year low of $11.63 and a 1-year high of $25.00.

Crispr Theraptc (NASDAQ:CRSP) last released its quarterly earnings results on Thursday, August 10th. The company reported ($0.56) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.62) by $0.06. Crispr Theraptc had a negative return on equity of 47.46% and a negative net margin of 406.61%. The company had revenue of $3.60 million during the quarter, compared to analysts’ expectations of $3.29 million. Crispr Theraptc’s revenue for the quarter was up 350.0% on a year-over-year basis. On average, analysts expect that Crispr Theraptc will post ($2.43) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Crispr Theraptc (CRSP) Director Kurt Von Emster Sells 35,473 Shares” was posted by BNB Daily and is the property of of BNB Daily. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The original version of this news story can be accessed at https://www.baseball-news-blog.com/2017/08/20/crispr-theraptc-crsp-director-sells-660861-99-in-stock-updated.html.

Institutional investors have recently added to or reduced their stakes in the stock. Wellington Management Group LLP raised its position in Crispr Theraptc by 0.4% in the first quarter. Wellington Management Group LLP now owns 747,450 shares of the company’s stock valued at $16,272,000 after buying an additional 3,070 shares during the last quarter. Credit Suisse AG acquired a new position in Crispr Theraptc during the first quarter valued at approximately $1,742,000. Paulson & CO. Inc. acquired a new position in Crispr Theraptc during the first quarter valued at approximately $1,099,000. Monashee Investment Management LLC increased its stake in Crispr Theraptc by 208.7% in the first quarter. Monashee Investment Management LLC now owns 22,186 shares of the company’s stock worth $473,000 after buying an additional 15,000 shares during the period. Finally, Vanguard Group Inc. purchased a new stake in Crispr Theraptc during the second quarter worth about $273,000. Hedge funds and other institutional investors own 24.08% of the company’s stock.

Several research analysts recently commented on the company. Chardan Capital reissued a “buy” rating on shares of Crispr Theraptc in a research note on Monday, August 14th. Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of Crispr Theraptc in a research note on Tuesday, July 18th. Cann assumed coverage on Crispr Theraptc in a report on Monday, July 17th. They issued a “market perform” rating for the company. Finally, SunTrust Banks, Inc. assumed coverage on Crispr Theraptc in a report on Thursday, July 13th. They issued a “hold” rating and a $16.00 target price for the company. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $21.92.

About Crispr Theraptc

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Insider Buying and Selling by Quarter for Crispr Theraptc (NASDAQ:CRSP)

Receive News & Ratings for Crispr Theraptc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Theraptc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply